CBD: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment. | conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment. | ||
Recent research into the use of CBD (cannabidiol) for treating glioblastoma has shown promising results, particularly in its potential impact on overall survival (OS). One study | Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates. | ||
* Source: [https://www. | * Source: [https://www.thebraintumourcharity.org/news/phase-2-trial-cannabis-based-drug-glioblastomas-open-summer-2022/ Phase 2 trial of cannabis-based drug in glioblastomas to open in summer 2022] - The Brain Tumour Charity, 2022. | ||
Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings. | |||
* Source: [https:// | * Source: [https://clinicaltrials.gov/ct2/show/NCT01812603 A Study of Nabiximols (Cannabis Based Medicine) as Adjuvant Therapy to Temozolomide in Recurrent Glioblastoma] - ClinicalTrials.gov, 2023. | ||
Revision as of 12:51, 12 August 2024
| Property | Information |
|---|---|
| Drug Name | CBD (Cannabidiol) |
| FDA Approval | Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment |
| Used for | Investigational use in cancer treatment, including symptom management and potential anti-tumor effects |
| Clinical Trial Phase | Preclinical studies and early human trials for cancer |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy |
| OS without | Not specified |
| OS with | Not applicable; ongoing research into potential impacts on overall survival in cancer patients |
| PFS without | Not specified |
| PFS with | Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. |
Notes: CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers, conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.
- Source: Phase 2 trial of cannabis-based drug in glioblastomas to open in summer 2022 - The Brain Tumour Charity, 2022.
Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings.
- Source: A Study of Nabiximols (Cannabis Based Medicine) as Adjuvant Therapy to Temozolomide in Recurrent Glioblastoma - ClinicalTrials.gov, 2023.
From Ben Williams Book: Not specified
